Chavda, JaydeepsinhJaydeepsinhChavdaBhavsar, KrishnaKrishnaBhavsarGupta, SharadSharadGuptaGupta, ItiItiGupta2025-08-312025-08-312021-10-0110.1142/S10884246215012612-s2.0-85118478937https://d8.irins.org/handle/IITG2025/25256The synthesis and biological studies of BODIPY-GPR peptide conjugate (BD-2) are reported. As compared to the parent BODIPY (BD-1), the peptide linked BD-2showed blue shifted absorption and emission with excellent Stokes shift of 201 nm. Molecular docking studies on EGFR protein kinase indicated very efficient binding affinity of BD-2 as compared to the standard drug (Erlotinib). The cell viability experiments of BD-2on normal (HEK293T) and lung cancer (A549) cell lines indicated 85-95% viability. Bioimaging studies showed that, BD-2was able to penetrate the lung cancer cell line.falseBODIPY | BODIPY-Peptide Conjugate | Cytotoxicity | Molecular Docking | PeptideArticle109914091230-12391 October 20218arJournal9WOS:000718931500041